Janus Henderson Capital Funds Plc - Global Life Sciences Fund on Protagonist Therapeutics, Inc.
Thesis
Protagonist Therapeutics is an existing portfolio holding benefiting from progress in its drug pipeline. During August, the FDA approved a hepcidin mimetic associated with the company. The therapy regulates red blood cell production in a rare blood cancer, providing an important regulatory validation for the company's technology.
“a hepcidin mimetic that regulates red blood cell production in a rare blood cancer for portfolio holding Protagonist Therapeutics”